• Member News

Mogrify awarded $1.1M additional funding from SBRI Healthcare

• Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy • Follows Phase I SBRI funding, announced in April 2019

Coulter Partners secures Chief Scientific Officer for OxStem

Coulter Partners was very pleased to partner once again with OxStem Limited to secure the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer.

Coulter Partners secures Head of US Sales for Nanoform

Coulter Partners was delighted to partner once again with innovative nanoparticle medicine enabling company, Nanoform to secure the appointment of Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.

NEW REPORT SHOWS IMPACT OF DISCOVERY PARK COMMUNITY LAB ON STEM EDUCATION

FUTURE PLANS TO INSPIRE MORE STUDENTS & INCREASE RANGE OF ACTIVITIES

Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio

Cell line to be used to support research and development of biotherapeutics across therapeutic areas

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical

• PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka’s therapeutics discovery programmes • Programmes to initially focus on gene therapy applications of identified targets

Arecor to participate At PEPTalk 2020’s Protein Science Week In San Diego, CA, USA

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA on 20-24 January 2020.

The Oxford Science Park sponsors the OXBA Innovation Award for the fifth year

Oxford, UK, 13 January 2020 - Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2020's Oxfordshire Business Awards (OXBA).

Horizon Discovery to provide access to novel base editing technology

• Next-generation gene editing system has applications in development of cell and gene therapies • Base editing builds on CRISPR offering and will expand Horizon’s research tools and services • Horizon seeks partners to assess and shape platform development

Horizon Discovery signs collaboration and license agreement with Mammoth Biosciences

● Aims to develop the next generation of engineered CHO cell lines, to improve production of biotherapeutics ● Bioproduction is a key business unit within Horizon, this agreement underlines strategy to focus on core markets